康龙化成（北京）新药技术股份有限公司 关于股东解除一致行动关系的公告 证券代码：300759 证券简称：康龙化成 公告编号：2025-033 本公司股东厦门龙泰鼎盛企业管理合伙企业（有限合伙）、厦门龙泰汇盛企业 管理合伙企业（有限合伙）、厦门龙泰汇信企业管理合伙企业（有限合伙）、厦门龙 泰众盛企业管理合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次解除一致行动关系是因公司股东的普通合伙人暨执行事务合伙人发 生变更所致，不涉及股东持股数量变动； 2、本次一致行动关系解除不会导致公司实际控制人发生变化。 一、基本情况 郑北女士是公司实际控制人之一、董事、执行副总裁，在公司首次公开发行 股票并上市时，其作为员工持股平台的普通合伙人暨执行事务合伙人，实际控制 员工持股平台所持有公司股份的表决权，员工持股平台为郑北女士的一致行动人。 在一致行动关系存续期间，各方在公司重大事项的决策上始终保持一致意见，严 格履行相关承诺事项，不存在滥用自身控制地位的情形。 2025 年 6 月 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年6月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 | RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 | RMB | ...

Core Viewpoint - The Hong Kong stock market is expected to open higher, with a positive pre-market performance in the innovative drug sector, driven by significant approvals for new drugs in China [1] Group 1: Market Performance - The Hong Kong innovative drug index constituents saw notable gains, with Innovent Biologics rising over 6%, and other companies like Zai Lab and WuXi AppTec increasing by over 2% [1] - The Hong Kong innovative drug ETF (159567) experienced a net inflow of over 165 million yuan in the past 20 trading days, indicating high market enthusiasm [1] - The price-to-earnings ratio of the Hong Kong innovative drug index decreased from 64 times on February 21 to 27 times on June 4, highlighting improved value for investors [1] Group 2: Regulatory Developments - On May 29, the National Medical Products Administration of China approved 11 innovative drugs, including 7 first-class innovative drugs, marking a historic moment for the sector [1] - Over 20 first-class innovative drugs have been approved from January to May, setting a record for the same period in the past five years [1] - The Chinese pharmaceutical industry is transitioning from "follow-up innovation" to "global leadership," focusing on clinical value in key areas like targeted cancer therapies and immunotherapy [1] Group 3: Investment Opportunities - The innovative drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends like AI-enabled drug development and the expansion of domestic innovative drugs [1] - The innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from AI advancements and the introduction of new drug reimbursement policies [2] - The domestic innovative drug sector is expected to show strong growth and investment value in the first half of 2025, driven by ongoing international collaborations and the approval of new drugs [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in its net value and returns over various time frames [1] - As of June 3, 2025, the latest net value of the fund is 1.6391 yuan, with a growth of 0.96%. The fund's return over the past month is 7.34%, ranking 224 out of 4690 in its category. Over the past three months, the return is 7.88%, ranking 461 out of 4620, and since the beginning of the year, the return is 8.66%, ranking 977 out of 4568 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management Company in October 2014 [2]

一、股东股份质押及解除质押的基本情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）近日接到公 司实际控制人楼小强先生和郑北女士的函告，获悉楼小强先生和郑北女士将其所 持有的公司部分股份进行了质押和解除质押，具体情况如下： | | 是否为控 | | | 占公 | | 是否 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押 | 占其所 | 司总 | 是否 | 为补 | 质押起 | | 质押到 | | | 质押用 | | 名称 | 第一大股 | 数量 | 持股份 | 股本 | 为限 | 充质 | 始日 | | 期日 | | 质权人 | 途 | | | 东及其一 | （股） | 比例 | | 售股 | | | | | | | | | | 致行动人 | | | 比例 | | 押 | | | | | | | | | 实际控制 | | | | | | 2025 | 年 | 2026 | 年 | 中信证 券股份 | 置换存 量金融 | | ...

Group 1 - The core point of the news is that 康龙化成 (Pharmaron) has seen a stock increase of over 4% following the announcement of its investment in a healthcare fund [1] - 康龙化成's subsidiary, Pharmaron UK Limited, plans to invest $30 million in the BLC Healthcare USD Fund I L.P. as a limited partner [1][2] - The fund aims to raise approximately $100 million to invest in various securities and assets in the global biopharmaceutical and life sciences sectors, focusing on early and growth-stage projects for long-term capital appreciation [2] Group 2 - The investment will utilize the expertise of professional investment institutions in the biopharmaceutical industry [1] - The fund will have the discretion to invest in other investment funds or vehicles managed by third parties [2] - The investment strategy includes a wide range of securities, including equity, debt securities, and derivatives [2]

Group 1 - The company 康龙化成 (300759) announced that its wholly-owned subsidiary 康龙英国 plans to invest $30 million in BLC Healthcare USD Fund I L.P. using its own funds [1] - The target fundraising amount for the BLC Healthcare USD Fund I L.P. is approximately $100 million [1] - As of the announcement date, 康龙英国 is the largest contributor to the fund, with a subscription ratio of 85.71% [1]

证券代码：300759 证券简称：康龙化成 公告编号：2025-029 康龙化成（北京）新药技术股份有限公司 关于境外子公司参与境外股权投资基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、投资事项概述 为充分运用专业投资机构在生物医药行业内投资、研判的能力，康龙化成（北 京）新药技术股份有限公司（以下简称"公司"）的全资子公司 Pharmaron UK Limited（以下简称"康龙英国"）拟作为有限合伙人以自有资金认缴出资 3,000 万美元参与投资 BLC Healthcare USD Fund I L.P.（以下简称"基金"或"合伙企 业"）。2025 年 5 月 30 日，康龙英国签署了《Amended and Restated Agreement of Exempted Limited Partnership of BLC Healthcare USD Fund I L.P.》（以下简称 "《合伙协议》"）。 本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法》规定 的重大资产重组情况。根据《深圳证券交易所创业板股票上市规则 ...

Group 1 - The company is a global leader in the one-stop CRDMO service platform, providing comprehensive services for drug discovery, preclinical and clinical development, and commercial production for various therapies since its IPO in 2019 [1] - The company's revenue is expected to grow at a CAGR of 27.13% from 2018 to 2024, while net profit attributable to the parent company is projected to grow at a CAGR of 32.39% during the same period [1] - The number of projects and new order amounts continue to increase, with new orders expected to grow over 20% year-on-year in 2024, ensuring stable performance for the company [1] Group 2 - The global pharmaceutical R&D market remains robust, with strong outsourcing demand for CXO services [1] - According to Frost & Sullivan, the global market sizes for drug discovery CRO, clinical CRO, and CDMO in 2022 were $180 billion, $547 billion, and $749 billion, respectively, and are projected to grow to $359 billion, $818 billion, and $1,573 billion by 2027, with respective 5-year CAGRs of 14.8%, 8.4%, and 16.0% [1] - China's CXO companies are expected to increase their market share in global drug discovery CRO, clinical CRO, and CDMO from 17.7%, 10.8%, and 13.2% in 2022 to 25.3%, 22.2%, and 21.2% by 2027 [1] Group 3 - The company maintains a customer-oriented approach, with 74.84% of revenue in 2024 coming from clients using multiple services [2] - The company introduced over 900 new clients in 2024, contributing to 5.34% of revenue [2] - The company has established 21 operational entities globally, including 11 overseas, enhancing customer communication and reducing geopolitical risks [2] Group 4 - The company is expected to achieve revenues of 136.38 billion, 154.47 billion, and 176.27 billion yuan from 2025 to 2027, with growth rates of 11.10%, 13.26%, and 14.12% respectively [2] - Net profit attributable to the parent company is projected to be 18.15 billion, 21.18 billion, and 25.41 billion yuan for the same period, with growth rates of 1.20%, 16.69%, and 19.98% respectively [2] - The company is rated as a "buy" due to its unique integrated CRDMO capabilities and sufficient order backlog [2]

Pharmaron Beijing Co., Ltd. 康龙化成（北京）新药技术股份有限公司 2025 H Share Award and Trust Scheme 2025年H股奖励信托计划 1 Table of Contents 目录 | 1. | Definitions and Interpretation 定义和解释 | 1 | | --- | --- | --- | | 2. | General Introduction and Purpose of the Scheme 本计划概览与目的 | 5 | | 3. | Conditions 条件 | 7 | | 4. | Duration 期限 | 7 | | 5. | Administration 管理 | 7 | | 6. | Selection of Selected Participant 选定参与者的选择 | 10 | | 7. | Award Letter regarding Grant of Awards 奖励授予的奖励函 | 15 | | 8. | Receipt of Treasury H Shares by the Trustee ...